LYEL News and Press, Lyell Immunopharma Inc.

2026-03-06 16:55:56 ET Lyell Immunopharma, Inc. (LYEL) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM EST... Read the full article on Seeking Alpha For further details see: Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Confer...

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management...

2026-02-13 14:01:58 ET More on pharmaceuticals, biotech Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More BBH: Mature Biotech Exposure, But Limited Growth Ahead XPH: Healthcare Dashboard For January Most and least shorted m...

PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second-line setting The pivotal single-arm tr...

2025-12-24 08:30:00 ET Thesis Read the full article on Seeking Alpha For further details see: Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data

VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034 [1] , driven by a fundamental shift in how physicians combat cancer's most resistant forms. ...

2025-12-22 14:56:08 ET More on Lyell Immunopharma Lyell Immunopharma buys exclusive global rights to colorectal cancer drug Seeking Alpha’s Quant Rating on Lyell Immunopharma Historical earnings data for Lyell Immunopharma Financial information for Lye...

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 Canada NewsWire Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC , Dec. 19, 2025 /CNW/ --  USA News Group News Commentary – The recent FDA approval in November of th...

2025-12-09 06:15:06 ET H.C. Wainwright analyst issues BUY recommendation for LYEL on December 9, 2025 11:14AM ET. The previous analyst recommendation was Neutral. LYEL was trading at $28.36 at issue of the analyst recommendation. The overall analyst consensus : HOLD. ...

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting 83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-...